Optimi Health Completes Psilocybin Export to Australia for Patients With Treatment-Resistant Depression
Optimi's 5mg psilocybin capsules are prescribed in Australia for treatment-resistant depression. The export marks Optimi's third commercial shipment since launching the 5mg psilocybin capsules in September 2025. VANCOUVER, BC, June 29, 2026 /PRNewswire/ - Optimi Health Corp. (NASDAQ:...
Optimi's 5mg psilocybin capsules are prescribed in Australia for treatment-resistant depression. The export marks Optimi's third commercial shipment since launching the 5mg psilocybin capsules in September 2025. VANCOUVER, BC, June 29, 2026 /PRNewswire/ - Optimi Health Corp. (NASDAQ:...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.